Evaluation of favipiravir in the treatment of COVID-19 based on the real-world

References

• Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Vaira LA, Hopkins C, Salzano G, et al. Olfactory and gustatory function impairment in COVID-19 patients: italian objective multicenter-study. Head Neck. 2020;42(7):1560–1569.
   PubMed Web of Science ®Google Scholar
• Geremia N, Vito AD, Gunnella S, et al. A Case of Vasculitis-Like Skin Eruption Associated With COVID-19. Infectious Disease in Clinical Practice. 2020;28(6): e30–e31
   Web of Science ®Google Scholar
• De Vito A, Fiore V, Princic E, et al. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. PLoS One. 2021;16(3):e0248009.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Coronavirus disease (COVID-19) - statistics and research. [Accessed20 October 2021]. : https://ourworldindata.org/coronavirus
   Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19) a review. JAMA. 2020;323(18):1824–1836.
   PubMed Web of Science ®Google Scholar
• Artese A, Svicher V, Costa G, et al. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist Updat. 2020;53:100721.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46(4):977–981.
   PubMed Web of Science ®Google Scholar
• Dallocchio RN, Dessì A, De Vito A, et al. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? Eur Rev Med Pharmacol Sci. 2021;25(5):2435–2448.
   PubMed Web of Science ®Google Scholar
• Rafi MO, Bhattacharje G, Al-Khafaji K, et al. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19. J Biomol Struct Dyn. 2020;1–20.
   Web of Science ®Google Scholar
• Buonaguro L, Tagliamonte M, Tornesello ML, et al. SARS-CoV-2 RNA polymerase as target for antiviral therapy. J Transl Med. 2020;18(1):185.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Naydenova K, Muir KW, Wu LF, et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc Natl Acad Sci U S A. 2021;118:7.
   Web of Science ®Google Scholar
• Shannon A, Selisko B, Le NT, et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020;11(1):4682.
   PubMed Web of Science ®Google Scholar
• Du YX, Chen XP. Favipiravir: pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020;108(2):242–247.
   PubMed Web of Science ®Google Scholar
• Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): a Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016;13(3):e1001967.
   PubMed Web of Science ®Google Scholar
• Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana SV. Literature-based review of the drugs used for the treatment of COVID-19. Curr Med Res Pract. 2020;10(3):100–109.
   PubMedGoogle Scholar
• Kivrak A, Ulas B, Kivrak H. A comparative analysis for anti-viral drugs: their efficiency against SARS-CoV-2. Int Immunopharmacol. 2021 90 ;107232.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Driouich JS, Cochin M, Lingas G, et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat Commun. 2021;12(1):1735.
   PubMed Web of Science ®Google Scholar
• Kaptein SJF, Jacobs S, Langendries L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020;117(43):26955–26965.
   PubMed Web of Science ®Google Scholar
• Manabe T, Kambayashi D, Akatsu H, et al. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):489.
   PubMed Web of Science ®Google Scholar
• Prakash A, Singh H, Kaur H, et al. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol. 2020;52(5):414–421.
   PubMed Web of Science ®Google Scholar
• Shrestha DB, Budhathoki P, Khadka S, et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Higgins J, Higgins J. Cochrane handbook for systematic reviews of interventions. Chichester UK: John Wiley & Sons, Ltd; 2008.
   Google Scholar
• Egger M, Smith G, Davey SM, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(d5928):.
   PubMed Web of Science ®Google Scholar
• Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
   PubMed Web of Science ®Google Scholar
• Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406.
   PubMed Web of Science ®Google Scholar
• Balykova LA, Govorov AV, Vasilyev AO, et al. Characteristics of covid-19 and possibilities of early causal therapy. Results of favipiravir use in clinical practice. Infektsionnye Bolezni. 2020;18(3): 30–40
   Google Scholar
• Balykova LA, Pavelkina VF, Shmyreva NV, et al. Efficacy and safety of some etiotropic therapeutic schemes for treating patients with novel coronavirus infection (COVID-19). Pharm Pharmacol. 2020;8(3): 150–159
   Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study. Engineering (Beijing). 2020;6(10):1192–1198.
   PubMedGoogle Scholar
• Chen C, Zhang Y, Huang J, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021 12 683296.
   PubMed Web of Science ®Google Scholar
• Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166(3):949–954.
   PubMed Web of Science ®Google Scholar
• Dabbous HM, El-Sayed MH, El Assal G, et al. Safety and efficacy of Favipiravir versus hydroxychloroquine in management of COVID-19: a randomised controlled trial. Sci Rep. 2021;11(1):7282.
   PubMed Web of Science ®Google Scholar
• Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate Coronavirus Disease (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2021 73(3) ;531–534.
   Web of Science ®Google Scholar
• Khamis F, Al Naabi H, Al Lawati A, et al. Randomized controlled open label trial on the use of Favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;102:538–543.
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial. Eur J Pharm Sci. 2021;157:105631.
   PubMed Web of Science ®Google Scholar
• Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95:107522.
   PubMed Web of Science ®Google Scholar
• Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhang C, Zhu Q, et al. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial. Int Immunopharmacol. 2021;97:107702.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother. 2021;133:110825.
   PubMed Web of Science ®Google Scholar
• Bolarin JA, Oluwatoyosi MA, Orege JI, et al. Therapeutic drugs for SARS-CoV-2 treatment: current state and perspective. Int Immunopharmacol. 2021;90:107228.
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Garrigos ZE, Almeida NEC, et al. Treatment Considerations for COVID-19: a Critical Review of the Evidence (or Lack Thereof). Mayo Clin Proc. 2020;95(7):1454–1466.
   PubMed Web of Science ®Google Scholar
• Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022.
   PubMed Web of Science ®Google Scholar
• Pileggi GS, Ferreira GA, Reis A, et al. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Adv Rheumatol. 2021;61(1):60.
   PubMedGoogle Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:1.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li MX, Lu GD, et al. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: truth under the Mystery. Int J Biol Sci. 2021;17(6):1538–1546.
   PubMed Web of Science ®Google Scholar
• Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425–1433.
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–1041.
   PubMed Web of Science ®Google Scholar
• Zequn Z, Yujia W, Dingding Q, et al. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. Eur J Pharmacol. 2021 893 ;173813.
   PubMed Web of Science ®Google Scholar
• Costa P, Rusconi S, Mavilio D, et al. Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. AIDS. 2001;15(8):965–974.
   PubMed Web of Science ®Google Scholar
• Soleimanian S, Yaghobi R. Harnessing Memory NK Cell to Protect Against COVID-19. Front Pharmacol. 2020;11:1309.
   PubMed Web of Science ®Google Scholar
• Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nat Med. 2021;27(10):1674–1675.
   PubMed Web of Science ®Google Scholar
• Jeyaraman M, Muthu S, Bapat A, et al. Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19. Heliyon. 2021;7(7):e07635.
   PubMed Web of Science ®Google Scholar
• Reynard S, Gloaguen E, Baillet N, et al. Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. PLoS Negl Trop Dis. 2021;15(3):e0009300.
   PubMed Web of Science ®Google Scholar
• Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195–3204.
   PubMed Web of Science ®Google Scholar
• Kheirabadi D, Haddad F, Mousavi-Roknabadi RS, et al. A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. J Med Virol. 2021;93(5):2705–2721.
   PubMed Web of Science ®Google Scholar
• Sreekanth Reddy O, Lai WF. Tackling COVID-19. Using Remdesivir and Favipiravir as Therapeutic Options. Chembiochem. 2021;22(6):939–948.
   PubMed Web of Science ®Google Scholar